About Third Rock Ventures
Third Rock Ventures is a venture capital firm founded in 2007. It is primarily based out of Boston, United States. As of Sep 2026, Third Rock Ventures is an active investor, having invested in 76 companies, with 2 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Post IPO round of Lisata Overall, Third Rock Ventures portfolio has seen 20 IPOs and 27 acquisitions including key companies like Nurix Therapeutics, Blueprint Medicines and Tango Therapeutics. A lot of funds co-invest with Third Rock Ventures, with names like Google Ventures sharing a substantial percentage of its portfolio. Third Rock Ventures has team of 45 people including 9 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 4 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Third Rock Ventures' List of Top Investments
Third Rock Ventures has a portfolio of 76 companies. Their most notable investments are in Goldfinch and Edimer Pharma.Their portfolio spans across United States, France and Germany. They have invested in Life Sciences, High Tech, HealthTech and 3 other sectors, across stages such as Series A, Series B and 4 more. Here is the list of top investments by Third Rock Ventures:Nurix provides the platform for controlling the body natural protein level and regulation. It offers its candidate ubiquitin E3 ligases which helps in treating a broad range of disease by the breakdown of protein in the cell. The many pipelines if the company includes, CBL -B, BTX which are at the preclinical and other prior stages of approval. It also focus in developing the drug for treatment of cancer, small molecule, immunoncology agents and others.
Key facts about Nurix Therapeutics
- Founded Year: 2009
- Location: San Francisco (United States)
- Annual Revenue: $50M - $100M as on Nov 30, 2025
- Stage: Public
- Total Funding till date: $173M
- Employee Count: 381 as on Aug 31, 2026
- Investors: Bain Capital Life Sciences, Foresite Capital and 9 Others
- Latest Funding Round: Series B, Mar 26, 2020, $*****
- Highlight: Public
Developer of selective kinase inhibitors for patients with genomically defined cancers. Their approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Their ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets.
Key facts about Blueprint Medicines
- Founded Year: 2008
- Location: Cambridge (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2024
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $115M
- Employee Count: 692 as on Aug 31, 2026
- Investors: BVF Partners, Foresite Capital and 20 Others
- Latest Funding Round: Post IPO, Jun 30, 2022, $*****
- Highlight: Acquired
Tango Therapeutics is a biotech company developing novel drugs for the treatment of cancer. The company uses DNA sequencing and CRISPR-based screening to identify targets for specific subgroups of cancer patients. The company is discovering novel targets using synthetic lethality, where the cancer-causing alteration in a tumour suppressor gene creates a vulnerability that leads to the destruction of the tumour cell.
Key facts about Tango Therapeutics
- Founded Year: 2017
- Location: Cambridge (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $165M
- Employee Count: 181 as on Aug 31, 2026
- Investors: Bain Capital Life Sciences, Boxer Capital and 8 Others
- Latest Funding Round: Post IPO, Oct 24, 2025, $*****
- Highlight: Public
4. Bluebird Bio
Developer of gene therapies for severe genetic and rare diseases. The company's products include Lenti-D for Childhood Cerebral Adrenoleukodystrophy (ALD) and LentiGlobin for rare hemoglobinopathies. The company's other products for multiple myeloma and HPV-associated cancer are in the preclinical stage. The company is also using homing endonuclease and megaTAL gene-editing technologies in a variety of potential applications and disease areas, including hematology and oncology.
Key facts about Bluebird Bio
- Founded Year: 1992
- Location: Cambridge (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2024
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $136M
- Employee Count: 317 as on May 31, 2026
- Investors: RA Capital Management, Abn Amro and 10 Others
- Latest Funding Round: Post IPO, Jun 03, 2022, $*****
- Highlight: Acquired
Fulcrum Therapeutics is focused on discovering and developing small molecules that modulate the on/off control mechanisms that regulate genes. The Fulcrum product engine integrates insights from four scientific disciplines (Gene Regulation, Human Genetics and Disease, Cell Biology, and Screening and Computation) to identify novel drug targets and develop breakthrough medicines. The early focus of Fulcrum’s product engine is on two severe genetic diseases: Fragile X syndrome (FXS) and a form of muscular dystrophy called facioscapulohumeral muscular dystrophy (FSHD). Each disease arises from a single gene mutation that creates an error in gene regulation. In the case of Fragile X, the silencing of the FMR1 gene eliminates the cell’s ability to make a protein needed for brain function. In FSHD, the precipitating event is the activation of a gene called DUX4 that should be silent in adulthood. This activation leads to muscle wasting as cells die.
Key facts about Fulcrum Therapeutics
- Founded Year: 2015
- Location: Cambridge (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $115M
- Employee Count: 53 as on Jul 31, 2026
- Investors: Foresite Capital, Boxer Capital and 15 Others
- Latest Funding Round: Post IPO, Jun 10, 2020, $*****
- Highlight: Public
Third Rock Ventures' Year-on-Year Investment Trends
Third Rock Ventures has invested in 76 companies over the last 18 years, with an average of 3 new investments annually in the last 10 years. In 2025, it made 5 investments, while as of Sep 2026, it has made 3 investments in this year. Its most recent first time investment was in Lisata and most recent follow-on round was in Flare Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 2 | 3 |
2025 | 2 | 3 | 5 |
2024 | 4 | 3 | 7 |
2023 | 5 | 3 | 8 |
2022 | 2 | 3 | 5 |
2021 | 3 | 4 | 7 |
2020 | 3 | 5 | 8 |
2019 | 4 | 2 | 6 |
2018 | 4 | 3 | 7 |
2017 | 3 | 4 | 7 |
Third Rock Ventures' Investments by Stage
Third Rock Ventures is primarily an Early Stage Investor investor majorly investing in Series A (58) rounds where average round size is $3.31B, Series B (6) rounds where average round size is $178M and Series C (3) rounds where average round size is $370M.Stage of entry | No. of Investments |
|---|---|
Series A | 58 |
Series B | 6 |
Series C | 3 |
Series D | 2 |
Post IPO | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Third Rock Ventures' Investments by Sector
Third Rock Ventures has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Artificial Intelligence - Industry Applications. Notably, it has invested in 72 Tech companies, 69 Enterprise (B2B) companies, 11 Software companies and at least 5 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 71 |
High Tech | 16 |
Enterprise Applications | 6 |
HealthTech | 4 |
Artificial Intelligence - Industry Applications | 2 |
Others | 6 |
Note: We have considered here, only first round of investments
Third Rock Ventures' Investments by Geography
Third Rock Ventures has made most investments in United States (70), followed by France where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 70 |
France | 1 |
Note: We have considered here, only first round of investments
Third Rock Ventures' recent investments
Third Rock Ventures has made 3 investments in 2026 so far. Lisata and Flare Therapeutics are the latest among them.Here are the most recent investments by Third Rock Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 18, 2026 | United States | Post IPO | 7929 | [+11] | |
Jun 30, 2026 | United States | Series C | 9235 | [+9] | |
Apr 10, 2026 | United States | Series C | 7179 | ||
Dec 18, 2025 | France | Series A | 9088 | [+4] | |
Nov 04, 2025 | United States | Series A | 6570 |
IPOs and Publicly Listed companies in Third Rock Ventures' Portfolio
20 of Third Rock Ventures' portfolio companies have become public. Seaport Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in May 2026 at marketcap of $912M and Maze Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $700M.Here are Third Rock Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 01, 2026 | Apr 09, 2024 | Series A | 1076 | |
Jan 31, 2025 | Mar 01, 2019 | Series C | 5608 | |
Oct 25, 2024 | Jan 27, 2022 | Series A | 4516 | |
Jun 07, 2024 | Mar 07, 2023 | Series A | 6205 | |
Sep 04, 2020 | Mar 30, 2017 | Series A | 4546 |
Acquired companies in Third Rock Ventures' Portfolio
27 companies from Third Rock Ventures' portfolio have been acquired. The most recent acquisition was Marea Therapeutics in Sep 2026 by Lisata for $*****.Here are Third Rock Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 18, 2026 | - | - | 9229 | |
Aug 31, 2026 | Apr 09, 2025 | Series A | 7362 | |
May 03, 2026 | Sep 09, 2024 | Series D | 5913 | |
Jan 21, 2026 | Sep 18, 2026 | Post IPO | 9541 | |
Dec 03, 2025 | May 11, 2011 | Series A | 6946 |
Team profile of Third Rock Ventures
Third Rock Ventures has a team of 45 members including 9 Partners, 14 Venture Partners and 5 Principals located in United States and Canada. Third Rock Ventures' team sits on the board of 1 company.Here is a list of top team members in Third Rock Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Boston | - | ||
Partner | Boston | - | - | |
Partner | Waban | - | - | |
Partner | - | - | - | |
Partner | Palo Alto | - | - | |
Partner | Boston | - | - | |
Partner | - | - | - | |
Partner | Milton | - | - | |
Partner | Clinton | - | - | |
Venture Partner | Boston | - | - |
Co-investors of Third Rock Ventures
Over the past 18 years, 319 investors have co-invested in Third Rock Ventures's portfolio companies. This includes funds and angels.
- Invested before Third Rock Ventures: HHS, Easton Capital Investment Group and 15 others have invested in rounds before Third Rock Ventures. There are 3 companies where HHS has invested before Third Rock Ventures and 1 company where Easton Capital Investment Group has invested before Third Rock Ventures.
- Top Co-investors of Third Rock Ventures: 117 investors entered a company along with Third Rock Ventures. These include investors like Google Ventures (9 companies).
- Invested after Third Rock Ventures: A total of 185 investors have invested in Third Rock Ventures's portfolio after their investments. Top Investors include Casdin Capital (18 companies), Wellington (11 companies) and RA Capital Management (11 companies).
Recent News related to Third Rock Ventures
•
•
Terremoto Biosciences Raises $108M in Series C FundingFinSMEs•Apr 15, 2026•Terremoto, RA Capital Management, Deep Track Capital, Cormorant-asset and 4 others
•
Syremis Therapeutics Raises $165M in Series A FinancingFinSMEs•Dec 19, 2025•Pictet Group, QVT Family Office, Bain Capital Life Sciences, Dexcel and 3 others
•
•
•
T.Rx Capital closes $77M inaugural fundEndpoints•Sep 18, 2025•T.Rx Capital, Third Rock Ventures, Arch Venture Partners, Polaris Partners and 1 other
•
Artbio secures $132M funding as its alpha radioligand program enters clinical trialsEndpoints•Jul 29, 2025•Parabilis Medicines, ARTBIO, 3B Pharmaceuticals, Novartis and 9 others
•
Corvia Medical secures $55M funding to complete trial and pursue FDA approval for Atrial Shuntintelligence360•Jun 30, 2025•Corvia Medical, Lumira Ventures, Accelmed, General Catalyst and 1 other
•
•
Maze Therapeutics raises $115m to advance kidney disease candidatesPharmaceutical Technology•Dec 04, 2024•Maze Therapeutics, Deep Track Capital, Frazier Life Sciences, Logos and 7 others
